Skip to content
Heavy Metal Index

NLC-Based Sunscreen Formulations with Optimized

Source

This source page is a mechanical bulk-ingest record for a PDF in the research-pulls corpus.

Page snapshot
Cited by6 pages
Metals measured1
Evidence tierB
Year2024

Overview

This source page is a mechanical bulk-ingest record for a PDF in the research-pulls corpus. It preserves source-level identity, routeable product/analyte scope, and exact extracted numeric lines for later human or fresh-context audit. It does not derive HMTc thresholds, percentiles, or brand-by-brand comparisons.

Key numbers

The worker extracted the full PDF text with layout preservation twice and compared extraction hashes before commit. The following lines are copied from numeric/table-bearing regions of the PDF and retain the source units and wording where legible:

  • Junior, E.A.; Faro, R.; Azevedo, H. encapsulation efficiency (>90%), and drug content (>80%), which were preserved for at least 90 days
  • despite a 10% reduction in the total filters content. Altogether, these results describe the application
  • distributed under the terms and into three radiation ranges known as UVA (320 to 400 nm), UVB (290 to 320 nm), and
  • microparticle size range is acceptable, given their low percutaneous absorption (1,11,12);
  • instance, a 2-fold increase in SPF was reported when 20% (w/w) of a lipid-based nanocarrier
  • submitted to high-intensity probe sonication (20% amplitude) for 10 min, using a high-
  • lipid load (10%—the proportion of bacuri butter and raspberry seed oil is described in
  • patent application WO2023137532A1) and the total of filters (6%) were considered as main
  • model’s lack of fit were indicated by the analysis of variance (ANOVA, 95% confidence)
  • and their combination are shown in Tables 1 and 2, respectively. The evaluated response or
  • Table 2. 22 Face Centered Central Composite Design for NLCs formulation varying the proportion of
  • Table 1 shows the values of the factors’ levels. Finally, the response (CQA) evaluated was
  • of 80% cream bases (described in Section 2.12) and 20% SC-NLC or 20% purified water
  • 1%—mobile phase B. The mobile phase flow was 0.7 mL/min, and the chromatographic
  • The encapsulation efficiency (%EE) of Uvinul® A plus, Uvinul® T150, and Tinosorb® S
  • %EE = ((Ftotal − Ffree )/Ftotal ) × 100% (1)
  • %LC = ((Ftotal − Ffree )/Ltotal ) × 100% (2)
  • Analysis of variance (ANOVA, 95% confidence level) was used to compare the significant
  • After the surgery, the skin was stored in NaCl 0.9% solution and kept under refrigeration for
  • detection wavelength of 250 nm. The LOQ of this method was 0.35291, 0.00084, and
  • and non-pigmented cream bases in the proportions of 10, 20, and 30% for in vitro tests
  • and 20% for in vivo assays. The assembled tests carried out in this study followed the
  • The samples that were analyzed were (I) SC-NLC 100%, (II) Emulsion 100% (obtained
  • (III) Cream base SPF 30 and UVAPF 10 (CB-I), (IV) Cream base 80% (diluted with water),
  • (V) SC-NLC 20% (w/w) in the cream base, (VI) Emulsion in a cream base in the proportion
  • of 20% (w/w). The cream base (CB-I) presented in its composition 13.5% of chemical
  • or a total weight of 70 mg (±2.5%) under dark light. The samples were let dry for 15
  • of 1.25; consequently, the variation dose between sites was 25%. The median dose was
  • in vivo request a minimum of ten valid results, which is true when the 95% confidence
  • interval of the SPF mean is within 17% (37,38). Thus, we certify that this condition was
  • Several sample groups were included in this assay; they were (a) 80% cream base + 20%
  • purified water, (b) 80% cream base + 20% emulsion, and (c) 80% cream base + 20% SC-
  • 17, pigmented). The cream base CBII presented 15.86% of total chemical filters, which
  • ethylbutylphenol, and titanium dioxide. The CBIII presented 13.52%, composed of bis-
  • of the cream base compositions is presented in Table S1—Supplementary Materials.
  • evaluated by ANOVA and Tukey tests, using 95% confidence, and considered significantly
  • by the software Design Expert 13. In all tests, the used confidence interval was 95%, where
  • (solid lipid) and raspberry seed oil (liquid lipid), summing 10% of the formulation weight;
  • to 6.75% of Polysorbate 60. A broader range of the optimized region was reached when
  • the Polyglyceryl-3-dioleate ratio was 2.5%, in which SC-NLC presenting less than 300 nm
  • were produced in the range of 3 to 10% of Polysorbate 60. Additionally, the concentration
  • the Polyglyceryl-3-dioleate amount increases from 0 to 5%. The larger particle diameter

Methods (brief)

  • azone) were kindly donated by BASF (Mannheim, Germany). HPLC-grade ethanol and
  • can be easily scaled up in pharmaceutical industries. These samples were also obtained
  • sample with characteristics within the desired region. As aforementioned, the significant
  • samples were analyzed in a dilution of 200 times; the diluents used were water (DLS)
  • samples were prepared by solubilizing the filters with and without NLCs and bare-NLCs
  • The morphology of the optimized SC-NLC was evaluated by AFM. The sample was
  • speed of approximately 1 Hz to avoid damage to the sample surface.
  • 2.9.1. Standard and Sample Preparation
  • within three days. The sample preparation was performed as follows: (1) 100 µL of NLCs
  • A Plus, Tinosorb® S, and Uvinul® T150 in the sample solution is 48, 32, and 16 µg/mL,
  • were detected were 20 µL and 312 nm, respectively (32). The solutions prepared for HPLC
  • by HPLC, following the method described in Section 2.9.2. The encapsulation efficiency
  • is the concentration of the non-encapsulated chemical filter collected in the ultrafiltration-
  • the skin explant was covered with 300 µL of sample (SC-NLCs or emulsion) in the Franz
  • and epidermis of each replicate were mechanically separated by heating the skin sample
  • Following this, the supernatant of the sample was further analyzed by HPLC. The receptor
  • liquid was also sampled for further analysis. Then, the concentration of Uvinul® A Plus,
  • were determined by HPLC (Agilent 1100 HPLC System, DAD G1315B), using the column

Implications

This page makes the source discoverable for category-level evidence routing. Values remain source-native and should be used only with the stated matrix, species, basis, geography, and censoring context from the paper. The page does not convert total mercury to methylmercury or use total arsenic as inorganic arsenic.

Wiki pages this source may touch

Verification notes

  • Identity check: DOI, raw handle, candidate cite-key, and SHA-256 were compared against existing wiki/sources/ pages before creation.
  • Full-PDF read: pdftotext -layout was run on the full PDF twice; extracted text hashes matched before the page was written.
  • Numeric verification: numeric/table-bearing lines were selected mechanically from the verified extraction and preserved without unit conversion or rounding.
  • Brand firewall: the worker skips PDFs when extracted numeric lines appear brand/manufacturer-sensitive; this page contains category-level or species-level evidence only.
  • HMTc firewall: no threshold, percentile, pass/fail, clean/dirty, or certification math is stated.

Update history

The five most recent substantive edits to this page, classified major (evidence or structure moved), correction (a published value or statement was wrong and has been fixed), or minor (narrative rewritten without changing the underlying evidence). Each description is derived from what the edit did to this page; the linked commit is the authoritative record, routine regeneration passes are excluded, and the full version history lives in git. When DOI minting comes online (see schema docs), each entry below will also link to a version-pinned DataCite DOI.

CommitDateChangeDescription
b01ec52c2026-08-04major2 sections added
d49e450f2026-08-03major5 sections added; narrative text revised